Ludwig Institute for Cancer Research Limited

Medimmune Limited

Departemente D'immunologie Institut Henri Beaufour

Department D'immunologie Institut Henri Beaufour

Jacques Van Snick

Catherine Uyttenhove

Catherine Druez

Jean-Christophe Renauld

Richard John Simpson

Thierry Boon

Pierre G Coulie

Pierre Braquet

Pascal Chaux

Ursula Grohman

Bernard Dugas

Jean Christophe Renauld

Jean M Mencia-Huerta

Thierry R Boon-Falleur

Pierre Van Der Bruggen

William Dall'Acqua

Bernard Lethe

Vincent Stroobant

Kris Thielemans

Jennifer Lynne Reed

Erwin Schultz

Bernard Lethé

Pierre Van Der Bruggan

Thierry Boon-Fallaur

Jurgen Corthals

Carlo Heirman

M&eacute;lisande Richard

Francoise Cormont

Jochen Moeller

Lothar Hultner

Mélisande Richard

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

TGF-β3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-β1 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-&#x3b2;3) are provided, particularly recognizing human and mouse TGF-&#x3b2;3, particularly antibodies and fragments that do not recognize or bind TGF-&#x3b2;1 or TGF-&#x3b2;2. Particular antibodies are provided which specifically recognize and neutralize TGF-&#x3b2;3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&#x3b2;3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&#x3b2;3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-&#x3b2;3-9, MTGF-&#x3b2;3-12, MTGF-&#x3b2;3-16, MTGF-&#x3b2;3-17 and MTGF-&#x3b2;3-19, whose sequences are provided herein.

TGF-&#x3b2;3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-&#x3b2;1) are provided, particularly recognizing human and mouse TGF-&#x3b2;1 and not recognizing or binding TGF-&#x3b2;2 or TGF-&#x3b2;3. Particular antibodies are provided which specifically recognize and neutralize TGF-&#x3b2;1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&#x3b2;1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&#x3b2;1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

TGF-&#xdf;1 specific antibodies and methods and uses thereof

TGF-&#x3b2;1 specific antibodies and methods and uses thereof

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

Recombinant anti-interleukin-9 antibodies

The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0&#x2013;10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

MAGE-A1 peptides presented by HLA class II molecules

The methods of this invention relate to immunizing animals with conjugates of cytokines and a carrier to induce a prolonged high titre antibody response specific for the cytokine. This invention also relates to the treatment of pathological conditions, e.g., eosinophilia and allograft rejection, associated with the production of cytokines, in particular interleukins, e.g., IL-4, IL-5, IL-9, and IL-13, by immunization with the cytokine conjugates or by administration of antibodies specific for the cytokine. This invention also relates to compositions comprising the cytokine conjugates and the conjugates per se.

Method for making cytokine specific antibodies and uses thereof

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

Mage-A3 peptides presented by HLA class molecules

Method of treatment with IL-9 conjugate

The invention involves the recognition of IL-9 as a molecule involved in induction of IL-10. Administration of IL-9 leads to protection against conditions where IL-10 production is warranted, such as infections by Gram negative bacteria. Examples of such conditions are septic shock and endotoxemia. Also a part of the invention are methods of treatment where IL-9 and a phosphodiesterase inhibitor are administered to a subject. Compositions, such as kits which include these two components are a part of the invention, as is treatment of conditions involving excess IL-10 production by administering an IL-9 inhibitor.

Method for regulating IL-10 with IL-9, and applications thereof

The invention describes nucleic acid sequences which code for the interleukin 9 receptor (IL9-R) molecule. These sequences may be used as probes to identify cells expressing the molecule, and as agents to transfect recipient cells.

Methods for producing antibodies which specifically bind to

Growing community of inventors

Brussels, Belgium

Jacques Van Snick